Biofil Chemicals

Who are the top shareholders of the Biofil Chemicals?

The top shareholders of Biofil Chemicals include Scope Finance Company Private Limited with 13.9%, Starline Equifin Private Limited at 7.51%, and individual investors holding 38.31%. There are no pledged promoter holdings or mutual fund investments, and only one Foreign Institutional Investor holds a minimal stake.

The top shareholders of Biofil Chemicals include Scope Finance Company Private Limited, which holds the highest promoter stake at 13.9%. The highest public shareholder is Starline Equifin Private Limited, with a holding of 7.51%. Additionally, individual investors collectively hold 38.31% of the company's shares. There are no pledged promoter holdings and no mutual funds currently invested in the company. Only one Foreign Institutional Investor (FII) holds a stake, but it is minimal at 0.0%.

What does Biofil Chemicals do?

Biofil Chemicals & Pharmaceuticals Ltd manufactures and trades pharmaceutical products, classified as a Micro Cap company with a market cap of Rs 86 Cr. As of March 2025, it reported net sales of 8 Cr and a net profit of 0 Cr.

Overview: <BR>Biofil Chemicals & Pharmaceuticals Ltd is engaged in the manufacturing and trading of pharmaceutical products within the Pharmaceuticals & Biotechnology industry, classified as a Micro Cap company.<BR><BR>History: <BR>The company was incorporated as a Private Limited Company on January 4, 1985, and later converted into a Public Limited Company on May 7, 1992. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 8 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: Rs 86 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 89.00 <BR>Industry P/E: 35 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.01 <BR>Return on Equity: 2.99% <BR>Price to Book: 4.85<BR><BR>Contact Details: <BR>Address: 11/12 Sector E Sanwer Road, Sanwer Road Industrial Area Indore Madhya Pradesh : 452015 <BR>Tel: 91-731-2426700 <BR>Email: bcplcompliance@gmail.com <BR>Website: http://www.biofilgroup.net

Who are in the management team of Biofil Chemicals?

As of March 2023, the management team of Biofil Chemicals includes Ramesh Shah (Chairman & Managing Director), Romil Shah (Non Executive Director), Ketan Shah (Whole-time Director), and several Independent Directors: Shaila Jain, Satish Beohar, Ashok Kumar Ramawat, and Gayatri Padiyar, along with Shweta Verma as Company Secretary & Compliance Officer.

As of March 2023, the management team of Biofil Chemicals includes the following individuals:<BR><BR>1. Ramesh Shah - Chairman & Managing Director<BR>2. Romil Shah - Non Executive Director<BR>3. Shaila Jain - Independent Director<BR>4. Satish Beohar - Independent Director<BR>5. Ashok Kumar Ramawat - Independent Director<BR>6. Ketan Shah - Whole-time Director<BR>7. Shweta Verma - Company Secretary & Compliance Officer<BR>8. Gayatri Padiyar - Independent Director<BR><BR>Each member plays a distinct role within the organization, contributing to its governance and operational oversight.

Has Biofil Chemicals declared dividend?

No Dividend History Available

Who are the peers of the Biofil Chemicals?

Biofil Chemicals' peers include Sun Pharma, Divi's Lab, Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare. In terms of management risk, growth, and capital structure, Biofil Chemicals is rated average, with a 1-year return of -22.04%.

Peers: The peers of Biofil Chemicals are Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, Dr Reddy's Labs, Rajnish Wellness, Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at Sun Pharma.Inds., Divi's Lab., Cipla, Torrent Pharma, and Dr Reddy's Labs, while Average management risk is found at Rajnish Wellness and Biofil Chemicals. Below Average management risk is noted at Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare. For growth, Excellent growth is seen at Sun Pharma.Inds., Cipla, and Dr Reddy's Labs, while Below Average growth is noted at Biofil Chemicals, Divi's Lab., Torrent Pharma, Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare. Capital Structure is Excellent for Sun Pharma.Inds., Divi's Lab., Cipla, and Dr Reddy's Labs, Good for Torrent Pharma and Biofil Chemicals, Average for Lasa Supergeneri, and Below Average for Rajnish Wellness, Achyut Healthcar, Sunil Healthcare, and Godavari Drugs.<BR><BR>Return Snapshot: Divi's Lab. has the highest 1-year return at 51.96%, while Rajnish Wellness has the lowest at -83.83%. Biofil Chemicals' 1-year return is -22.04%, which is significantly lower than the highest and higher than the lowest. Additionally, peers such as Rajnish Wellness, Achyut Healthcar, Lasa Supergeneri, and Sunil Healthcare have negative six-month returns.

Is Biofil Chemicals overvalued or undervalued?

As of November 11, 2024, Biofil Chemicals is considered overvalued with a PE ratio of 87.13 and an EV to EBIT ratio of 87.37, underperforming the market with a year-to-date return of -6.93% and a low ROE of 2.99%.

As of 11 November 2024, Biofil Chemicals has moved from a valuation grade of very expensive to expensive. The company is currently considered overvalued, with a PE ratio of 87.13, an EV to EBIT ratio of 87.37, and a Price to Book Value of 4.74. These ratios indicate a significant premium compared to its peers, such as Sun Pharma with a PE of 35.25 and Divi's Lab at 79.33, both of which are also in the expensive to very expensive range.<BR><BR>In comparison to the broader market, Biofil Chemicals has underperformed on a year-to-date basis, with a return of -6.93% against the Sensex's 5.66%. This trend, combined with its high valuation ratios and low ROE of 2.99%, suggests that the stock may not justify its current price level, reinforcing the conclusion that it is overvalued.

What is the technical trend for Biofil Chemicals?

As of May 5, 2025, Biofil Chemicals shows a mildly bearish trend overall, with mixed signals from various indicators, including a mildly bullish weekly MACD and bearish monthly MACD, alongside daily moving averages that are also mildly bearish.

As of 5 May 2025, the technical trend for Biofil Chemicals has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD remains bearish, suggesting mixed signals across time frames. The Bollinger Bands show a bullish trend on the weekly chart but are mildly bearish on the monthly, further indicating a lack of strong momentum. Moving averages on the daily chart are mildly bearish, which aligns with the overall trend. The KST and Dow Theory both present a mildly bullish outlook on the weekly, but remain mildly bearish on the monthly. Overall, the current technical stance is mildly bearish, with key indicators such as the daily moving averages and monthly MACD contributing to this view.

How big is Biofil Chemicals?

As of 24th July, Biofil Chemicals & Pharmaceuticals Ltd has a market capitalization of 76.00 Cr, with recent net sales of 33.40 Cr and a net profit of 0.55 Cr over the last four quarters.

As of 24th July, <BR><BR>Market Cap: Biofil Chemicals & Pharmaceuticals Ltd has a market capitalization of 76.00 Cr and is classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 33.40 Cr, while the sum of Net Profit for the same period is 0.55 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2024, with Shareholder's Funds amounting to 18.20 Cr and Total Assets valued at 47.08 Cr.

When is the next results date for Biofil Chemicals?

The next results date for Biofil Chemicals is 12 August 2025.

The next results date for Biofil Chemicals is scheduled for 12 August 2025.

How has been the historical performance of Biofil Chemicals?

Biofil Chemicals has experienced fluctuating financial performance, with net sales declining from 40.04 Cr in March 2024 to 33.40 Cr in March 2025, alongside decreased profitability and negative cash flow in the latest fiscal year. Total assets and liabilities increased, indicating a challenging financial environment.

Answer:<BR>The historical performance of Biofil Chemicals shows fluctuations in net sales and profitability over the years, with a notable decline in recent periods.<BR><BR>Breakdown:<BR>Biofil Chemicals reported net sales of 33.40 Cr in March 2025, down from 40.04 Cr in March 2024, but an increase from 30.04 Cr in March 2023. The total operating income followed a similar trend, peaking at 40.04 Cr in March 2024 and showing a decrease to 33.40 Cr in March 2025. The company's total expenditure, excluding depreciation, was 32.55 Cr in March 2025, down from 39.22 Cr in March 2024. Operating profit (PBDIT) for March 2025 was 1.16 Cr, slightly lower than 1.31 Cr in March 2024. Profit before tax decreased to 0.74 Cr in March 2025 from 0.87 Cr in March 2024, while profit after tax was 0.56 Cr in March 2025, compared to 0.71 Cr in March 2024. The company's total assets increased to 50.96 Cr in March 2025 from 47.08 Cr in March 2024, with total liabilities also rising to 50.96 Cr from 47.08 Cr. The cash flow from operating activities turned negative at -1.00 Cr in March 2025, contrasting with a positive cash flow of 2.00 Cr in March 2024. Overall, the data indicates a challenging financial environment for Biofil Chemicals, with declining sales and profitability in the latest fiscal year.

Are Biofil Chemicals & Pharmaceuticals Ltd latest results good or bad?

Biofil Chemicals & Pharmaceuticals Ltd's latest results are concerning, showing a 461.83% revenue growth from a low base, but a drastic 96.68% decline in net profit to ₹0.08 crore and low operating margins indicate significant operational challenges and weak financial health. Investors should exercise caution due to the volatility in earnings.

Biofil Chemicals & Pharmaceuticals Ltd's latest results present a mixed picture that leans more towards negative than positive. While the company reported a significant year-on-year revenue growth of 461.83%, this figure is somewhat misleading as it compares against a very low base from the previous year. In terms of net profit, the company posted only ₹0.08 crore in Q2 FY26, which represents a staggering decline of 96.68% compared to the previous quarter.<BR><BR>The operating margin has improved slightly to 0.89% from 0.16% in Q1 FY26, but this is still alarmingly low, indicating that the company is struggling to generate meaningful profit from its core operations. Additionally, the profit after tax (PAT) margin has dropped dramatically from 37.48% in Q1 to just 0.59% in Q2, raising concerns about the sustainability of its earnings.<BR><BR>Overall, while the revenue growth appears impressive at first glance, the sharp decline in profitability and the low operating margins suggest significant operational challenges. Investors should be cautious, as the underlying financial health of the company seems weak, and the volatility in its earnings raises questions about future performance.

Should I buy, sell or hold Biofil Chemicals & Pharmaceuticals Ltd?

Why is Biofil Chemicals & Pharmaceuticals Ltd falling/rising?

As of 17-Mar, Biofil Chemicals & Pharmaceuticals Ltd's stock price is rising to 30.78, up 2.7%, driven by strong relative performance and increased investor participation. However, it has seen significant declines over the past month and year, suggesting the current rise may be temporary.

As of 17-Mar, Biofil Chemicals & Pharmaceuticals Ltd's stock price is rising, currently at 30.78, reflecting an increase of 0.81 or 2.7%. This upward movement can be attributed to several factors. Firstly, the stock has outperformed its sector by 2.42% today, indicating strong relative performance compared to its peers. Additionally, there has been a notable increase in investor participation, with the delivery volume rising by 11.49% against the 5-day average, suggesting growing interest among investors.<BR><BR>Despite these positive indicators, it is important to note that the stock has experienced a decline over longer periods, including a 1-month drop of 11.45% and a 1-year decline of 31.02%. However, the current rise in price may be a response to short-term market dynamics rather than a reversal of the longer-term trend. The stock is currently trading higher than its 5-day moving averages, although it remains below the 20-day, 50-day, 100-day, and 200-day moving averages, indicating mixed signals regarding its overall trend.

Why is Biofil Chemicals & Pharmaceuticals Ltd falling/rising?

As of 18-Mar, the stock price of Biofil Chemicals & Pharmaceuticals Ltd is at 30.55, reflecting a decline of 0.75%. The stock has experienced significant losses over various periods, including an 11.24% drop in the past month and a 30.88% decline over the past year, indicating a bearish trend.

As of 18-Mar, the stock price of Biofil Chemicals & Pharmaceuticals Ltd is falling, currently at 30.55, which reflects a decrease of 0.23 or 0.75%. This decline is evident in its performance today, where it underperformed its sector by 1.02%. Over the past month, the stock has experienced a significant drop of 11.24%, compared to a lesser decline of 8.40% in the benchmark Sensex. <BR><BR>Additionally, the stock has shown a negative trend over longer periods, with a year-to-date decline of 10.49% and a staggering 30.88% drop over the past year. The three-year and five-year comparisons also reveal a downward trajectory, with losses of 25.14% and 54.06%, respectively, while the Sensex has gained 32.27% and 55.85% in those same periods.<BR><BR>Investor participation appears to be waning, as indicated by a delivery volume of 5.7k on 17 March, which has decreased by 32.65% compared to the five-day average. Furthermore, while the stock is currently higher than its five-day moving average, it remains below the 20-day, 50-day, 100-day, and 200-day moving averages, suggesting a bearish trend. Overall, these factors contribute to the stock's current decline.

Why is Biofil Chemicals & Pharmaceuticals Ltd falling/rising?

As of 19-Mar, Biofil Chemicals & Pharmaceuticals Ltd is facing a decline in stock price, currently at Rs 30.26, reflecting a -0.82% change. The stock has underperformed significantly over various time frames and is trading below its moving averages, indicating a bearish trend amid declining investor interest and a broader sector downturn.

As of 19-Mar, Biofil Chemicals & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 30.26, which reflects a change of -0.25 (-0.82%). The stock has been underperforming, having fallen consecutively for the last two days with a total decline of -5.46% during this period. Additionally, the stock is close to its 52-week low, being only 3.75% away from Rs 28.01.<BR><BR>In terms of broader performance, the stock has shown negative returns across various time frames, including a -30.13% decline over the past year, while the benchmark Sensex has only decreased by -1.65% in the same period. Over three years, the stock has fallen by -25.85%, contrasting sharply with the Sensex's gain of +27.97%. <BR><BR>Today's trading activity indicates a lack of investor interest, as the delivery volume has decreased by -2.27% compared to the five-day average. Furthermore, the stock is trading below its moving averages across multiple time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, suggesting a bearish trend. The overall sector, Pharmaceuticals & Drugs, has also declined by -2.13%, contributing to the negative sentiment surrounding Biofil Chemicals. <BR><BR>These factors collectively indicate that the stock is falling due to poor performance metrics, declining investor participation, and a broader sector downturn.

Why is Biofil Chemicals & Pharmaceuticals Ltd falling/rising?

As of 20-Mar, Biofil Chemicals & Pharmaceuticals Ltd's stock price is Rs 29.34, down 3.04%, with significant underperformance compared to the Sensex. The stock has declined 16.05% over the past month and is close to its 52-week low, reflecting a persistent bearish trend and decreasing investor confidence.

As of 20-Mar, Biofil Chemicals & Pharmaceuticals Ltd is experiencing a decline in its stock price, currently at Rs 29.34, which reflects a change of -0.92 or -3.04%. The stock has been underperforming significantly, with a 1-week decline of -4.43% compared to a negligible -0.04% drop in the Sensex. Over the past month, the stock has decreased by -16.05%, while the benchmark index has fallen by only -10.00%. Year-to-date, the stock is down -14.03%, again underperforming the Sensex, which has declined by -12.54%.<BR><BR>The stock is currently close to its 52-week low, being only 4.53% away from Rs 28.01. It has been on a downward trend, having fallen for three consecutive days, resulting in a total decline of -4.68% during this period. Additionally, Biofil Chemicals is trading below its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a persistent bearish trend.<BR><BR>Investor participation appears to be decreasing, as evidenced by a delivery volume of 8.04k on March 19, which is down by -3.48% compared to the 5-day average. This decline in trading activity suggests a lack of confidence among investors, contributing to the stock's falling price. Overall, the combination of poor performance relative to the market, consecutive losses, and reduced investor engagement are key factors driving the decline in Biofil Chemicals & Pharmaceuticals Ltd's stock price.

Which are the latest news on Biofil Chemicals?

Which are the latest news on Biofil Chemicals?

Which are the latest news on Biofil Chemicals?